NOVARTIS AG ADR

NYSE: NVS (Novartis AG)

最近更新时间: 4天之前, 6:30PM

160.50

0.25 (0.16%)

前收盘价格 160.25
成交量 1,402,761
预期市盈率 (P/E Forward) 16.01
价格/销量 (P/S) 5.36
股市价格/股市净资产 (P/B) 8.13
52周波幅
123.24 (-23%) — 170.46 (6%)
股息率 (DY TTM) 3.20%
营业毛利率 24.16%
营业利益率 (TTM) 35.40%
稀释每股收益 (EPS TTM) 6.38
季度收入增长率 (YOY) 12.40%
季度盈利增长率 (YOY) 34.20%
总债务/股东权益 (D/E MRQ) 81.32%
流动比率 (MRQ) 0.790
营业现金流 (OCF TTM) 19.00 B
杠杆自由现金流 (LFCF TTM) 13.89 B
资产报酬率 (ROA TTM) 11.42%
股东权益报酬率 (ROE TTM) 32.89%

AIStockmoo 评分

0.9
价值 30% -0.1
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考
相对其盈利增长,估值偏低。 参考
当前股价隐含每年 16.5% 的盈利增长;公司业务可支撑约每年 12.3% 的增长。 参考
历史估值 参考 NA
负债低。盈利能力强。短期流动性偏紧。现金流为正。 参考
资本回报 参考 NA
时机 30% 2.8
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年呈上升趋势。股价接近52周高点。 参考
K线形态 参考 NA
您持有期的趋势 参考 NA
市场情绪 20% 0.1
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻好坏参半或中性。 参考
聪明钱 20% 0.2
内部交易活动 参考 NA
机构在最新13F申报中净+0.10%的股份:613家增持,792家减持(截至30 Sep 2026的季度)。 参考
市场和行业状况中性。
市场环境偏谨慎。 参考
行业表现优于大市。
只有一个支柱有明确读数,评分不变。
不计入评分
股价高于其52周平均水平。5年来上涨。 参考
短、中、长期趋势均向上。短期动能上升。 参考
股价接近支撑位。支撑与阻力水平趋降。 参考
最终评分 0.90

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看涨
Drug Manufacturers - General (全球的) 混合的 看涨
股票 Novartis AG 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B
NVS - 3.20% - 8.13
MRK - 2.31% - 8.12
LLY - 0.63% - 31.94
JNJ - 1.92% - 8.44
PFE - 6.00% - 1.85
ABBV - 3.18% - -

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Core
机构持股比例 7.16%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 6.65%

持仓变动 机构数 股数
增持 613 11,680,759
减持 792 14,292,134
新建仓 119 5,808,515
清仓 138 1,248,490

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

5 正面 3 负面 4 中性
日期 类型 细节
13 Nov 2026 Yahoo Finance Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more than half developing symptoms during adolescence4,5 Basel, November 13, 2026 – Novartis today announced…
13 Nov 2026 Yahoo Finance Novartis eyes Rhapsido’s broader use on positive urticaria data drop
Novartis will now approach regulators in a bid to expand Rhapsido’s label as analysts foresee a blockbuster future for the drug.
12 Nov 2026 Yahoo Finance New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients achieved a treatment response by Week 1 in SD and ColdU vs placebo Rhapsido was well tolerated…
12 Nov 2026 Yahoo Finance Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
12 Nov 2026 Yahoo Finance Thin Film Drug Manufacturing - Global Strategic Business Report 2026: Secure Share of a $14.3B Market by 2032 | Features Competitive Intelligence on Novartis, Pfizer, Indivior, IntelGenx and MonoSol Rx
Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Thin Film Drug Manufacturing - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global thin film drug manufacturing market was valued at US$8 billion in 2025 and is projected to reach US$14.3 billion by 2032…
11 Nov 2026 Yahoo Finance Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data
Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease.
11 Nov 2026 Yahoo Finance Is Novartis (SWX:NOVN) A Bargain Or Fully Priced Now?
Novartis has delivered strong multi year gains for shareholders, yet the recent run leaves a clear question on the table about whether the current share price is still aligned with what its earnings can support. With new clinical data, pipeline setbacks and safety headlines all in play, the issue…
11 Nov 2026 Yahoo Finance Advanced Therapy Medicinal Products - Global Strategic Business Report: Capitalize on 11.8% CAGR to Secure $25.4B by 2030 as Novartis, Gilead, Bristol-Myers Squibb and Roche Compete
R&D investment, strategic partnerships, scalable manufacturing and expedited approvals unlock ATMP commercialization amid rising demand for personalized therapies.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Advanced Therapy Medicinal Products - Global Strategic Business Report" has been added to…
11 Nov 2026 Yahoo Finance Novartis (SWX:NOVN) Halts Pelacarsen After Trial Miss As Ianalumab Data Impresses
Novartis (SWX:NOVN) halted development of its cardiovascular drug pelacarsen after a late stage outcome trial failed to meet its goal. The decision affects Novartis' efforts in cardiovascular risk reduction, a major therapeutic area for large patient populations. Novartis reported long term…
10 Nov 2026 Yahoo Finance Former Novartis CEO on What AI Can’t Replace in the Workplace
What risks do companies face as AI transforms the workplace—and what do they risk losing in pursuit of greater productivity? Former Novartis CEO Joe Jimenez discusses what businesses need to consider as they embrace AI in a conversation with Poppy Harlow at the WSJ Leadership Institute Board of…
10 Nov 2026 Yahoo Finance How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis
TG Therapeutics is Tuesday's IBD Stock Of The Day. Shares topped a buy zone despite a mixed Q3 report, but are in range of an alternate entry.
10 Nov 2026 Yahoo Finance Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low disease activity at Week 1081 Improvements in stimulated salivary flow were maintained in patients with…
显示更多
股息率 (DY TTM) 3.20%
5年平均股息收益率 2.15%
股息支付比率 62.60%
除息日 公告日期 支付日期 详情
12 Mar 2025 20 Feb 2025 - 3.869541 现金
09 Mar 2023 02 Feb 2023 20 Mar 2023 3.4693612 现金
08 Mar 2022 03 Feb 2022 17 Mar 2022 3.3252497 现金
04 Mar 2021 26 Jan 2021 15 Mar 2021 3.1990725 现金
03 Mar 2020 31 Jan 2020 12 Mar 2020 3.0873655 现金
04 Mar 2019 31 Jan 2019 13 Mar 2019 2.834128 现金
06 Mar 2018 07 Mar 2018 25 Apr 2018 2.936451 现金
01 Mar 2017 - 20 Apr 2017 2.717759 现金
24 Feb 2016 - 15 Apr 2016 2.717946 现金
02 Mar 2015 - 20 Apr 2015 2.665947 现金
27 Feb 2014 - 10 Apr 2014 2.759789 现金
26 Feb 2013 - 05 Apr 2013 2.42647 现金
27 Feb 2012 - 05 Apr 2012 2.482145 现金
24 Feb 2011 - 08 Apr 2011 2.36336 现金
02 Mar 2010 - 13 Apr 2010 1.948359 现金
24 Feb 2009 - 06 Apr 2009 1.714383 现金
26 Feb 2008 - 11 Apr 2008 1.537471 现金
06 Mar 2007 - 10 Apr 2007 1.096517 现金
28 Feb 2006 - 03 Apr 2006 0.880052 现金
01 Mar 2005 - 06 Apr 2005 0.88322 现金
24 Feb 2004 - 30 Mar 2004 0.78117 现金
04 Mar 2003 - 07 Apr 2003 0.70553 现金
21 Mar 2002 - 22 Apr 2002 0.4557 现金
22 Mar 2001 - 20 Apr 2001 0.4213 现金
12 Apr 2000 - 11 May 2000 0.8195 现金
21 Apr 1999 - 24 May 1999 0.8097 现金
21 Apr 1998 - 19 May 1998 0.7109 现金
16 Apr 1997 - 15 May 1997 0.5785 现金
26 Feb 1997 - 19 Mar 1997 3.234 现金
17 Apr 1996 - 16 May 1996 0.5156 现金
01 May 1995 - 31 May 1995 0.418 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2023 3.47 1 3.44
2022 3.33 1 3.67
2021 3.20 1 3.66
2020 3.09 1 3.27
2019 2.83 1 2.99
2018 2.94 1 3.82
2017 2.72 1 3.61
2016 2.72 1 4.16
2015 2.67 1 3.46
2014 2.76 1 3.32
2013 2.43 1 3.37
2012 2.48 1 4.38
2011 2.36 1 4.61
2010 1.95 1 3.69
2009 1.71 1 3.52
2008 1.54 1 3.45
2007 1.10 1 2.25
2006 0.880 1 1.71
2005 0.883 1 1.88
2004 0.781 1 1.73
2003 0.706 1 1.72
2002 0.456 1 1.39
2001 0.421 1 1.29
2000 0.820 1 2.04
1999 0.810 1 2.47
1998 0.711 1 1.62
1997 3.81 2 10.46
1996 0.516 1 2.00
显示更多

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票